Hey Guys and Gals,
Thought might be time to share a little research on Anteobind and how it is being utilised by others around the world with very good success.
The progress has taken a long time to be commercially recognized (I have been following it for near on a decade) but the last 12-24 months has seen many more research papers written and published by external companies, research institutes and labs utilising Anteobind to make life easier, faster and tests possible in labs around the world.
Here are a few examples of a few recently published papers using Anteobind for a wide range of uses.
1. Feb 2020
Study into porcupine reproductive and respiratory virus using anteobind for activation of surface
Initial trail results of a magnetic biosensor for the rapid detection of Porcine Reproductive and Respiratory Virus (PRRSV) infection - ScienceDirect2. May 2021
NMI Germany study Testing vaccine effectiveness for Covid using Anteobind for bead coupling
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals | Nature Communications3. August 2021
Study into vaccine effectiveness in people on haemodialysis using Luminex beads and anteobind
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis - ScienceDirect4. December 2021
NMI Germany study- Testing antibody effectiveness to Covid using Luminex beads and Anteo Magplex activation kits
COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants (medrxiv.org)5. January 2022
77E study testing methods for bacteria repellent or bacteria adhesive surfaces using Anteobind
Biosensors | Free Full-Text | Development and In-Depth Characterization of Bacteria Repellent and Bacteria Adhesive Antibody-Coated Surfaces Using Optical Waveguide Biosensing | HTML (mdpi.com)
6. January 2022
China Meat research center- study testing multiplex test for salmonella, listeria and e-coli using Anteobind for bead activation
Rapid and simultaneous detection of Salmonella spp., Escherichia coli O157:H7, and Listeria monocytogenes in meat using multiplex immunomagnetic separation and multiplex real-time PCR | SpringerLink
7. January 2022
Hungarian study into COVID crossing blood brain barrier utilising Anteobind biosensor
Biomedicines | Free Full-Text | Penetration of the SARS-CoV-2 Spike Protein across the Blood–Brain Barrier, as Revealed by a Combination of a Human Cell Culture Model System and Optical Biosensing | HTML (mdpi.com)8. Feb 2022
Indian study into Peptide based electrochemical detection of covid spike protein utilising Anteobind Biosensor
Peptide-Based Direct Electrochemical Detection of Receptor Binding Domains of SARS-CoV-2 Spike Protein in Pristine Samples by T. H. Vignesh Kumar, Sowmiya Srinivasan, Vinoth Krishnan, Rama Vaidyanathan, Kannadasan Anand Babu, Sudhakar Natarajan, Murugan Veerapandian :: SSRN9. Feb 2022
Austrian study using Anteobind for 2D printing of biomolecules to glass surfaces
Biosensors | Free Full-Text | A Simplified and Robust Activation Procedure of Glass Surfaces for Printing Proteins and Subcellular Micropatterning Experiments | HTML (mdpi.com)
10. March 2022
Multiplex study for identifying Alzheimer's disease using Anteobind
Nanoparticle-based multiplex biosensor utilising dual dielectrophoretic forces for clinical diagnosis of Alzheimer’s disease - ScienceDirectIt definitely appears Anteobinds surface modification properties are being recognized much more broadly, there were very few papers published prior to 2020 using Anteobind as a surface modifier. Now all the above in last 18-24 months and it is growing rather quickly with more added so far this year then in the last decade.
Now revenue for selling lab study materials and quantities of Anteobind is negligible..... but its a foot into the doors of the lab and some of these studies using Anteobind will lead to future products like what has been seen with Ellume.
One Ellume contract may not turn this into a multi billion dollar business but more ongoing supply contracts will certainly help the cause going forward. Hence more exposure and labs, scientists, organizations using Anteobind the more follow through will happen in this part of the business.
It also shows the very broad market for future tests that can be targeted in house using Eugeni platform from viral to bacterial infections, to veterinary uses and tests to brain and heart ailments and also food safety testing all of it is possible and plausible.
Todays announcement will be a major turning point for the company as a whole, the board have moved and have done what was needed....the time had arrived.
If they can find the right new management structure (it appears life science is well covered for now with Chris, Ian, Pierre and Charlie) and replicate this with battery divisions and manufacturing divisions along with seeking to put in the right people at the top with the drive & ambition to build a global & diverse multibillion dollar company but also the skills and knowledge to back it up it will be a monumental turning point.
The tech is finally being recognized as world leading and the company have the two lead scientists spreading the message loud and clear with Charlie presenting this week on Friday as an expert speaker in Madrid on behalf of Merck, while Manuel takes the exceptional battery anode results to the world battery stage in Orlando next week.
The science teams are kicking major goals its time for the company to engage commercialization experts and negotiators, along with inspiring leadership to take the scientists hard work to the next level.
Never been a better time to be an Anteo holder in my opinion then right now, after confirmation of new management today its back to buy for me.
(might one day share some of my findings and research on batteries that is super exciting)
GLTA.
(20min delay)
